Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$289.0M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1165.84%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$378.1M
Q3 2024
Cash
Q3 2024
P/E
-3.377
Nov 29, 2024 EST
Free Cash Flow
-$34.30M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $28.97M $21.45M $19.41M $13.16M $5.290M $1.480M
YoY Change 35.06% 10.51% 47.52% 148.77% 257.43%
% of Gross Profit
Research & Development $122.2M $80.80M $70.33M $36.20M $21.35M $13.68M
YoY Change 51.28% 14.88% 94.29% 69.58% 56.04%
% of Gross Profit
Depreciation & Amortization $50.00K $65.00K $79.00K $60.00K $17.00K $10.00K
YoY Change -23.08% -17.72% 31.67% 252.94% 70.0%
% of Gross Profit
Operating Expenses $151.2M $102.2M $89.74M $49.36M $26.64M $15.16M
YoY Change 47.88% 13.94% 81.83% 85.27% 75.73%
Operating Profit -$151.2M -$102.2M -$89.74M -$49.36M
YoY Change 47.88% 13.94% 81.83%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $4.794M $1.922M -$400.0K
YoY Change 149.43% -580.5%
% of Operating Profit
Other Income/Expense, Net $17.68M $2.164M -$526.0K -$203.0K -$30.56M -$990.0K
YoY Change 716.82% -511.41% 159.11% -99.34% 2986.87%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$138.3M -$102.0M -$90.27M -$49.56M -$57.20M -$16.15M
YoY Change 35.6% 13.0% 82.15% -13.36% 254.19%
Income Tax $3.867M $19.00K -$147.0K -$59.00K $218.0K $30.00K
% Of Pretax Income
Net Earnings -$142.2M -$102.0M -$90.12M -$49.50M -$57.42M -$16.18M
YoY Change 39.37% 13.21% 82.07% -13.79% 254.88%
Net Earnings / Revenue
Basic Earnings Per Share -$2.00 -$2.93 -$4.48
Diluted Earnings Per Share -$2.00 -$2.93 -$4.484M -$3.076M -$4.164M -$1.342M

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $578.9M $188.2M $150.7M $204.6M $93.30M $11.20M
YoY Change 207.65% 24.84% -26.33% 119.29% 733.04%
Cash & Equivalents $316.2M $55.26M $52.43M $98.20M $93.30M $11.20M
Short-Term Investments $262.7M $132.9M $98.29M $106.4M
Other Short-Term Assets $14.66M $7.920M $11.26M $5.500M $2.000M $100.0K
YoY Change 85.15% -29.68% 104.76% 175.0% 1900.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $593.5M $196.1M $162.0M $210.2M $95.30M $11.30M
YoY Change 202.7% 21.05% -22.94% 120.57% 743.36%
Property, Plant & Equipment $2.339M $455.0K $150.0K $200.0K $200.0K $0.00
YoY Change 414.07% 203.33% -25.0% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $396.0K $289.0K $290.0K $700.0K $100.0K $0.00
YoY Change 37.02% -0.34% -58.57% 600.0%
Total Long-Term Assets $2.735M $744.0K $440.0K $900.0K $300.0K $100.0K
YoY Change 267.61% 69.09% -51.11% 200.0% 200.0%
Total Assets $596.3M $196.8M $162.4M $211.1M $95.60M $11.40M
YoY Change
Accounts Payable $8.585M $12.50M $6.843M $2.100M $1.000M $1.500M
YoY Change -31.33% 82.7% 225.86% 110.0% -33.33%
Accrued Expenses $21.03M $12.11M $10.19M $6.000M $4.600M $1.200M
YoY Change 73.6% 18.81% 69.9% 30.43% 283.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $2.500M
YoY Change -100.0%
Total Short-Term Liabilities $29.61M $24.61M $19.54M $8.100M $5.600M $4.400M
YoY Change 20.3% 25.99% 141.2% 44.64% 27.27%
Long-Term Debt $24.80M $19.69M $16.90M $0.00 $0.00 $0.00
YoY Change 25.92% 16.53%
Other Long-Term Liabilities $5.557M $687.0K $30.00K
YoY Change 708.88% 2190.0%
Total Long-Term Liabilities $30.35M $20.38M $16.93M $0.00 $0.00 $0.00
YoY Change 48.94% 20.38%
Total Liabilities $59.96M $44.99M $36.47M $8.100M $5.600M $4.400M
YoY Change 33.27% 23.38% 350.19% 44.64% 27.27%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 71.17M 34.81M 20.10M
Diluted Shares Outstanding 71.17M 34.81M 20.10M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $975.93 Million

About 89bio, Inc.

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company is headquartered in San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2019-11-11. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. The company conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.

Industry: Pharmaceutical Preparations Peers: Evelo Biosciences, Inc. Kronos Bio, Inc. LianBio RIGEL PHARMACEUTICALS INC Cartesian Therapeutics, Inc. Summit Therapeutics Inc. Voyager Therapeutics, Inc.